Data on AstraZeneca vaccine insufficient for Swiss approval
Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing.
Copyright 2021 The Associated Press. All Rights Reserved
This content was published on
2 minutes
Keystone-SDA/gw
Español
es
Los datos de AstraZeneca son insuficientes para aprobación en Suiza
The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
But this did not mean that he believes the vaccine is a poor one.
“We are only saying that the company has not yet been able to prove to us that it is a good vaccine,” said Bruhin.
The approvals process, he added, was about hard data and facts. Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing, and remains in regular contact with the makers of the vaccine.
Other countries, such as the United Kingdom, have been administering the AstraZeneca vaccine for over three months – although several nations have halted vaccinations in recent days over isolated cases of blood-clotting. The European Medicines Agency has said the benefits of the Oxford-AstraZeneca jab greatly outweigh the risks and on Thursday will issue a report on its investigation into cases of blood clots.
Switzerland has ordered more than 35 million doses of Covid-19 vaccines from five manufacturers. To date Swissmedic has approved shots developed by Pfizer/BioNTech and Moderna. Roughly 4% of the population has been vaccinated so far, but delays in approval and delivery have slowed the roll-out process.
Popular Stories
More
Foreign Affairs
How a top Swiss university is screening Chinese students
Two decades after tsunami, Swiss tourists flock to Southeast Asia
This content was published on
Twenty years after a catastrophic tsunami in Southeast Asia, the region is again a top destination for Swiss, including at Christmas.
Swiss forests better equipped for storms 25 years after Lothar
This content was published on
Twenty-five years after Hurricane Lothar wreaked havoc in Switzerland, the country’s forests are now better prepared, experts say.
Media: Swiss medical services done abroad are billed at Swiss rates
This content was published on
In Switzerland, some medical services carried out abroad are still billed at Swiss rates, despite costing less, RTS reports.
This content was published on
Sophie Hediger, a member of the Swiss national snowboard cross team, has died in an avalanche in Arosa. She was 26 years old.
This content was published on
Several Swiss films exceeded the 100,000 admissions mark worldwide in 2024 and received widespread praise at international film festivals.
Swiss Alpine resorts covered in white gold for Christmas
This content was published on
Many areas at low altitudes in Switzerland are enjoying a blanket of snow. In the mountains, intense precipitation has delighted skiers.
SWISS makes emergency landing in Austria after smoke in cockpit
This content was published on
Swiss International Airlines (SWISS) made an emergency landing of an Airbus in Graz, Austria on Monday evening after engine problems.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland could sell or give away AstraZeneca doses if regulator dithers
This content was published on
A lack of green light from medicines regulator Swissmedic could see 5.3 million doses ordered by Switzerland sent elsewhere.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.